EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AI-Based Multi-Omics Approaches in Gynecological Cancers: A Review of Diagnostic, Prognostic, and Therapeutic Applications

Maedeh Mirasheh, Zahra Shahabinia, Mai Abdel Haleem A. Abusalah, Afrooz Mazidimoradi, Leila Allahqoli, Hamid Salehiniya, Do-Youn Lee

Journal of Clinical Medicine · 13.11.2026 · 15 (22) · 8907

DOI: 10.3390/jcm15228907 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 13.11.2026. Verfasst von Maedeh Mirasheh und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gynecological cancers, particularly ovarian, endometrial, and cervical cancers, have a high disease burden in terms of incidence and mortality, and their diagnosis and treatment remain challenging. AI-based multi-omics approaches integrate multilayer data, enabling comprehensive modeling and clinical decision-making. This narrative review aimed to critically examine the current and prospective applications of these approaches in three common gynecological cancers and to evaluate their clinical potential.

Methods

In this narrative review, following searches of PubMed, Web of Science, Scopus, and Google Scholar and screening of 1254 records, 51 original studies were included and synthesized qualitatively and descriptively. Relevant systematic reviews and meta-analyses were consulted only for contextualization and were not included in the primary evidence synthesis.

Results

AI-based multi-omics approaches in gynecological cancers may help distinguish cancer from healthy tissue, benign from malignant conditions, and early from advanced stages; identify molecular subgroups; predict survival and recurrence; predict responses to chemotherapy and immunotherapy; and discover therapeutic targets. Minimally invasive biofluids and machine learning models showed better performance than CA125 and HE4 in some studies. Factors such as the tumor microenvironment, immunity, LDHA, and ITGA1 were associated with drug resistance in computational or preclinical studies, whereas HRD and TP53 alterations are clinically validated determinants of platinum response. In cervical cancer, the evidence was more limited and heterogeneous. Overall, the findings are promising but preliminary, and further extensive clinical validation is needed.

Conclusions

AI-based multi-omics approaches may contribute to early diagnosis, molecular classification, prognostic assessment, and treatment selection in gynecological cancers; however, they remain at the proof-of-concept and initial validation stages. Prospective, multicenter, standardized studies with external validation are necessary for clinical application. These tools may serve as complementary approaches to current diagnostic pathways.

Zitieren

APA

Mirasheh, M., Shahabinia, Z., Abusalah, M. A. H. A., Mazidimoradi, A., Allahqoli, L., Salehiniya, H., & Lee, D. (2026). AI-Based Multi-Omics Approaches in Gynecological Cancers: A Review of Diagnostic, Prognostic, and Therapeutic Applications. Journal of Clinical Medicine, 15(22), 8907. https://doi.org/10.3390/jcm15228907

Vancouver

Mirasheh M, Shahabinia Z, Abusalah MAHA, Mazidimoradi A, Allahqoli L, Salehiniya H, et al. AI-Based Multi-Omics Approaches in Gynecological Cancers: A Review of Diagnostic, Prognostic, and Therapeutic Applications. Journal of Clinical Medicine. 2026;15(22):8907. doi:10.3390/jcm15228907

BibTeX
@article{Mirasheh2026,
  author = {Mirasheh, Maedeh and Shahabinia, Zahra and Abusalah, Mai Abdel Haleem A. and Mazidimoradi, Afrooz and Allahqoli, Leila and Salehiniya, Hamid and Lee, Do-Youn},
  title = {AI-Based Multi-Omics Approaches in Gynecological Cancers: A Review of Diagnostic, Prognostic, and Therapeutic Applications},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {22},
  pages = {8907},
  doi = {10.3390/jcm15228907}
}
Kostenlos starten →